Commissioner Hamburg on R&D Productivity
This article was originally published in RPM Report
Executive Summary
The following is an excerpt from FDA Commissioner Margaret Hamburg’s keynote address to the Food & Drug Law Institute annual meeting in Washington April 4.
You may also be interested in...
FDA Rethinking Weight Loss Standards: A Test Case for Patient-Focused Drug Development
The Center for Drug Evaluation & Research is working with George Washington University as a “neutral convener” to rethink weight loss drug development standards. That may make for an unexpected legacy from the wave of failed weight loss candidates from 2010: a whole new approach to drug development guidance from FDA.
A Case Study in Regulatory Innovation: Pharmacogenomics at FDA
FDA’s idea to encourage “voluntary” submission of pharmacogenomic data started slow—but the program has paid significant dividends for the agency. In addition to building knowledge and advancing the use of PKG in drug regulation, it has also won over industry and become a case study to support broader funding of regulatory science.
Regulatory Science: A Legislator's Perspective
Agriculture Appropriations Subcommittee Chair Rosa DeLauro is a critical figure in FDA’s quest to secure expanded resources to support regulatory science. The good news: she believes in the cause. The bad news: she has a lot of other changes she would like to see at FDA.